Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TBS 2025

Next Previous
Drug Profile

TBS 2025

Alternative Names: KVA-001; KVA-002; KVA-12.1; KVA-12123; TBS-2025

Latest Information Update: 14 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GigaGen
  • Developer TuHURA Biosciences
  • Class Antibodies; Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; VISTA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Preclinical Acute myeloid leukaemia; Colorectal cancer; Non-small cell lung cancer

Most Recent Events

  • 01 Apr 2026 TuHURA Biosciences plans a meeting with the FDA to discuss the development plan for TBS-2025 in NPM1 mut r/r Acute Myeloid Leukemia in June 2026
  • 01 Apr 2026 TuHURA Biosciences plans a phase Ib/II trial for Acute myeloid leukaemia (Second-line therapy or greater)(IV) in the second half of 2026
  • 23 Mar 2026 TuHURA Biosciences plans to initiate a clinical trial for TBS 2025 for Hematologic Malignancies (Monotherapy, Combination therapy) in the US in early second quarter of 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top